Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-301, CDX-1140, and SBRT in Advanced NSCLC
NCT04491084Phase 2Terminated
- Sponsor
- Albert Einstein College of Medicine
- Start
- Jan 2021
- Primary completion
- Aug 2022
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Flt3 ligand, CDX-1140 in non-small cell lung cancer (NSCLC), sponsored by Albert Einstein College of Medicine. Started Jan 2021; status: terminated.
02
Drugs
Flt3 ligandCDX-1140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04491084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04491084.